Taste, Nutrition & Health

The GLP-1 opportunity and beyond

The global weight management landscape is rapidly transforming, driven by the emergence of GLP-1* receptor agonists (GLP-1 RAs) like semaglutide and tirzepatide. This trend signals a shift towards food options that can support healthier lifestyles, with consumers prioritizing nutrient-dense foods and scientifically validated solutions. Post-pandemic, health has become a primary driver for food and beverage choices, fostering a holistic view that integrates nutrition and overall well-being, encompassing both physical and mental health.

As overweight and obesity rates continue to rise globally, consumers are actively seeking more effective methods for weight management. This growing health awareness and popularity of GLP-1 RAs pushes the demand for integrated wellness strategies which creates a significant market opportunity for the food and beverage industry.

Symrise, with its portfolio and market expertise, is well positioned to help manufacturers navigate the rapidly changing weight management landscape and partner with them for food and beverage innovations that address evolving consumer needs.

Featured content
Symrise Food & Beverage Trend UpdateMore

Inspiring market insights


* GLP-1 is a hormone your body releases after eating. It helps to control blood sugar by boosting insulin, slowing digestion, and reducing appetite, leading to a feeling of fullness.

GLP-1 receptor agonists (GLP-1 RAs) are medications that mimic and act like this hormone. They can help to manage diabetes and obesity by lowering blood sugar and often reducing appetite, which can lead to weight loss.

Woman drinking an isotonic drink whike exercising

Consumer interest goes beyond GLP-1 drugs

The advent and increasing accessibility of GLP-1 RAs have dramatically disrupted the weight management sector. These medications mimic a hormone that regulates blood sugar and appetite, leading to significant weight loss by effectively reducing hunger and promoting prolonged feelings of satiety. They also quiet the so-called "food noise" (obsessional food thoughts even in absence of physiological needs) by targeting brain regions that control satiety and reward signaling.

As users experience reduced appetite, overall food intake decreases. Eating less can lead to reduced protein or micronutrient intake if meals are not well planned. Therefore, nutrient-dense choices are emphasized. As satiety occurs earlier, each bite should provide meaningful nutritional value. These recommendations, coupled with changing taste preferences, lead GLP-1 users to prefer good-for-you products (e.g., low sugar, high protein, high fiber), minimally processed foods like fruits, vegetables, meat and fish, and functional nutrition products like protein drinks, meal replacements and bars. Foods like ready meals, sweets, sugary drinks and salty snacks are under pressure.

GLP-1 RAs are the most prominent example for prescription drugs for weight management, but consumers go beyond: They are interested in all products supporting them in reaching their weight management goals – be it prescription drugs or non-medical solutions like functional food and beverages. This shift presents both a challenge and a clear opportunity for the industry to adapt and innovate, offering products with high nutritional value and other supportive solutions for this growing consumer base of people aiming to manage their weight.

weight loss infographic
Person eating a healthy meal and looking at their smartphone

Filling the innovation gap

While the focus on weight management is intensifying, there remains a significant opportunity to innovate beyond existing product formulations. The opportunity lies in developing food and beverage innovations focusing on several key strategic pillars:

Would you like to learn how our solutions can support you in developing food and beverage innovations that support consumers’ weight management journeys? 
 

Contact us